ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Translational Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1575156

This article is part of the Research TopicOptimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety ProfilesView all 6 articles

The glucagon-like peptide-1, fibroblast growth factor 21, and other endocrine responses to alcohol ingestion in women before and after metabolic surgery

Provisionally accepted
  • 1Medicine, University of Illinois at Urbana-Champaign, Champaign, United States
  • 2Carle Foundation Hospital, Urbana, Illinois, United States

The final, formatted version of the article will be published soon.

Glucagon-like peptide-1 (GLP-1) is integral to glucose homeostasis, appetite, and reward pathways in the brain, making GLP-1 receptor agonists effective treatments for type 2 diabetes, obesity, and potentially alcohol use disorder (AUD). Although metabolic surgery increases endogenous GLP-1, it is paradoxically associated with a higher risk of AUD. Building on cross-sectional research indicating that alcohol consumption decreases endogenous GLP-1 and may contribute to a heightened risk of hypoglycemia post-metabolic surgery, this longitudinal, within-subject study examined whether acute alcohol intake reduced GLP-1 and increased fibroblast growth factor 21 (FGF21)-a liver-derived hormone implicated in glucose regulation and alcohol consumption in animal models-more profoundly after surgery. Seven women were assessed using a randomized, crossover design; they consumed after overnight fast a standardized alcohol-containing beverage or placebo during two separate visits before surgery and repeated these interventions ~5 months post-surgery. Blood samples were collected over three hours to measure blood alcohol concentration (BAC), and plasma glucose, GLP-1, FGF21, insulin, and C-peptide. Results demonstrated that post-surgery, BAC peaked faster and at higher concentrations, and alcohol clearance decreased by ~28%-likely reflecting the loss of fat-free mass. However, the acute GLP-1 decrease and profound FGF21 increase following alcohol intake were not magnified in the postoperative period, nor did alcohol-induced reductions in glucose become more pronounced. These findings suggest that, despite substantial weight loss and improvements in insulin sensitivity, acute alcohol consumption in the fasted state elicits comparable effects on GLP-1, FGF21, and glycemia before and a few months after metabolic surgery. Further studies with larger and more diverse cohorts are warranted to confirm these observations, clarify long-term effects on alcohol metabolism and glycemic control, and inform strategies to mitigate the potential risk of AUD in this population.

Keywords: Trial Registration: NCT02766322 ethanol, Bariatric (weight-loss) surgery, gut peptides, Hypoglycemia, Insulin, pharmacokinetic

Received: 11 Feb 2025; Accepted: 05 May 2025.

Copyright: © 2025 Molina-Castro, Rowitz and Pepino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Marta Yanina Pepino, Medicine, University of Illinois at Urbana-Champaign, Champaign, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.